2024年1至12月份，奥赛康的营业收入构成为：医药制造业占比97.92%，其他业务占比2.08%。 （文章来源：每日经济新闻） 奥赛康（SZ 002755，收盘价：26.35元）8月15日晚间发布公告称，北京奥赛康药业股份有限公司股东 中亿伟业控股有限公司持有公司股份约1.2亿股，占公司总股本的约12.95%。中亿伟业计划在本公告披 露之日起15个交易日后的3个月内，以集中竞价和大宗交易方式减持公司股份不超过约1856万股，不超 过公司总股本的2%。 ...

Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9772 yuan, reflecting a growth of 1.81% [1]. - The fund's return over the past month is 9.64%, ranking 129 out of 328 in its category [1]. - Over the last six months, the fund has achieved a return of 47.35%, ranking 12 out of 316 [1]. - Year-to-date, the fund has a return of 45.00%, ranking 18 out of 316 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Rejig Bio: 5.63% - Kelun Pharmaceutical: 5.02% - HAO OBO: 4.36% - BeiGene: 3.61% - Yifang Bio: 3.58% - Aosaikang: 3.52% - Bid Pharma: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the fund management industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 证券代码：002755 证券简称：奥赛康 公告编号：2025-042 北京奥赛康药业股份有限公司 关于持股 5%以上股东减持计划的预披露公告 持股 5%以上的股东中亿伟业控股有限公司保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 北京奥赛康药业股份有限公司（以下简称"公司"）股东中亿伟业控股有限公 司（以下简称"中亿伟业"）持有本公司股份 120,192,033 股，占本公司总股本的 12.9495%。中亿伟业计划在本公告披露之日起 15 个交易日后的 3 个月内，以集 中竞价和大宗交易方式减持本公司股份不超过 18,563,200 股，不超过本公司总股 本的 2%。 现将有关情况公告如下： 一、股东的基本情况 1、 股东名称：中亿伟业控股有限公司 2、 截至本公告日，中亿伟业持有本公司股份 120,192,033 股，占本公司总 股本的 12.9495%，该等股份全部为无限售流通股。 二、本次减持计划的主要内容 （一）本次拟减持的具体安排 1、 减持原因：股东经营发展需要。 2、 股份来源： ...

Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9462 yuan, reflecting a growth of 2.54% [1]. - The fund's return over the past month is 11.14%, ranking 101 out of 333 in its category [1]. - Over the last six months, the fund has achieved a return of 46.50%, ranking 10 out of 327 [1]. - Year-to-date, the fund has returned 42.73%, ranking 18 out of 327 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Hotgen Biotech: 5.63% - Kelun Pharmaceutical: 5.02% - HAOYOBIO: 4.36% - BeiGene: 3.61% - Eucure Biopharma: 3.58% - Aosaikang: 3.52% - Bide Pharmaceutical: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the financial industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

（文章来源：证券日报） 证券日报网讯奥赛康8月11日在互动平台回答投资者提问时表示，截至7月31日，公司的股东人数为20， 229户。 ...

Summary of the Conference Call for Aosaikang Industry and Company Overview - The conference call focuses on Aosaikang, a company in the pharmaceutical industry, particularly in the fields of generic drugs and innovative drugs [2][3][4]. Key Points and Arguments Generic Drug Business - Aosaikang's generic drug business has shown signs of recovery following the PPI collection, with new generics like Rabeprazole and key products like Delafloxacin set to launch, contributing to cash flow [2][3]. - The chemical drug collection rules are becoming more predictable and moderate, leading to stable profit releases from the generic drug business [2][3]. Innovative Drug Development - Aosaikang's first innovative drug, Ligatinib (for EGFR mutation non-small cell lung cancer), is expected to launch in 2025, with a significant market potential but facing intense competition [2][3][5]. - The Claudin 18.2 monoclonal antibody is anticipated to be the first domestically produced drug in China, particularly promising in the gastric cancer field [2][3][5]. - Other innovative drugs, such as Mavacitamab and dual antibodies for ophthalmology, are progressing steadily, with plans to submit one application and launch one product each year [2][3][5]. Smart Platform Technology - The Smart platform utilizes masking peptide technology to control the release of active ingredients, addressing issues related to short half-lives and high toxicity of traditional cytokine therapies [2][4][6]. - This technology is applicable across various treatment modalities, including antibodies and ADCs, and has shown potential in multiple therapeutic areas [4][6]. Market Competition and Challenges - The domestic EGFR TKI market is highly competitive, with eight third-generation EGFR TKIs already available. Aosaikang faces competition from companies like Innovent Biologics, which has strong commercialization capabilities [3][13]. - The Claudin 18.2 market is also competitive, with existing products showing varying efficacy, but Aosaikang's combination therapies are expected to perform better [12]. Additional Important Insights - The engineering modifications in cytokine therapies aim to enhance efficacy by designing dual-function molecules and utilizing prodrug technologies to improve targeting and reduce side effects [9][10]. - Aosaikang's innovative platform is expected to significantly enhance immune therapy outcomes, with promising clinical data anticipated for products like SKG315 and SKG915 by the second half of 2025 [11]. - The overall outlook for Aosaikang is optimistic, with a recovery in the generic drug sector and a robust pipeline of innovative products supported by advanced technology platforms [14].

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **China A-shares market** and its performance in July 2025, highlighting solid price gains across various sectors [1][2]. Core Insights and Arguments - **Sector Performance**: - **Healthcare**: Led with a **13.5%** increase in July and **23.1%** year-to-date (YTD) performance, driven by recovering demand and strong drug pipelines [2][8]. - **IT**: Increased by **6.7%** in July and **14.7%** YTD, benefiting from Nvidia's resumption of sales to China [2][8]. - **Materials**: Gained **6.4%** in July and **18.0%** YTD, supported by government initiatives against overcapacity [2][9]. - **Energy**: Saw a **4.7%** increase in July but a decline of **1.8%** YTD [2]. - **Real Estate**: Increased by **4.5%** in July but declined **2.3%** YTD [2]. - **Financials**: Only **2.1%** increase in July and **10.5%** YTD, with some companies experiencing significant declines [2][10]. - **Market Drivers**: - The **CSI300** index rose **3.5%** in July, with improving liquidity and solid GDP growth of **5.2%** year-on-year (y-y) in Q2 2025 [5][39]. - **Net inflows** into A-shares totaled **US$193 million**, primarily in Financials, IT, and Materials, while Industrials and Consumer Discretionary saw outflows [5][14]. - **Macroeconomic Indicators**: - **GDP Growth**: China's GDP growth was **5.2%** y-y, with nominal GDP growth at **3.9%** y-y, indicating a decline in the GDP deflator to **-1.2%** [5][39]. - **Industrial Production**: Increased by **6.8%** y-y, with notable growth in high-tech sectors [5][42]. - **Retail Sales**: Grew by **4.8%** y-y, below expectations, indicating weak consumer sentiment [5][39]. - **Trade**: Exports rose **5.8%** y-y, with a rebound in exports to the US [5][41]. Additional Important Insights - **Margin Financing**: The margin buying as a percentage of A-share turnover rose to **10.5%** at the end of July from **9.6%** at the end of June, indicating increased investor confidence [5][24]. - **Fund Issuance**: Equity mutual fund issuance remained stable at **Rmb18 billion** in July, compared to **Rmb21 billion** in June [5][27]. - **Shareholding Structure**: By the end of 2024, retail investors held **42%**, controlling shareholders **43%**, domestic financial institutions **12%**, and foreign investors **3%** of A-shares' total market cap [5][28]. This summary encapsulates the key points from the conference call, providing a comprehensive overview of the current state of the China A-shares market and its underlying economic factors.

截至2025年8月4日15时，奥赛康股价报28.29元，较前一交易日下跌0.11元，跌幅0.39%。盘中股价波动 明显，最高触及28.67元，最低下探至26.31元，振幅达8.31%。当日成交量为238902手，成交金额6.50亿 元。 8月4日早盘时段，奥赛康曾出现快速反弹，在9点53分前后5分钟内涨幅超过2%，股价从26.83元拉升至 27元，期间成交额达2.39亿元。从资金流向看，当日主力资金净流入6244.05万元，近五个交易日累计净 流入1.31亿元。 风险提示：以上内容不构成投资建议，市场有风险，投资需谨慎。 奥赛康主营业务为化学制药领域，专注于创新药研发与生产。公司产品管线覆盖消化系统、抗感染等多 个治疗领域，其中幽门螺杆菌相关药物研发进展受到市场关注。作为北京地区医药企业代表，奥赛康在 细分领域具备技术积累。 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-08-01 | 002755 | 奥赛康 | 24.71 | 12.52 | 309.37 | 机构专用 | 华泰证券股份有限 | | | | | | | | | 公司南京分公司 | 8月1日，奥赛康大宗交易成交12.52万股，成交额309.37万元，占当日总成交额的0.55%，成交价24.71元，较市场收盘价28.4 元折价12.99%。 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical and biotechnology industry, emphasizing the transition from "Made in China" to "Created in China" for innovative drugs [10]. Core Insights - The report highlights that domestic innovative drugs are gaining global competitiveness and are currently in the first and second stages of international expansion, primarily through licensing agreements and partnerships [10][12]. - The report identifies key areas of focus for investment, including PD-(L)1 plus, ADCs, and GLP-1 drugs, which are expected to drive future growth and business development (BD) opportunities [10][51]. Summary by Sections Section 1: Transition from "Manufacturing" to "Innovation" - The policy reforms initiated in 2015 have stimulated a shift from generic to innovative drug development in China, with significant increases in R&D investment since 2018 [19][21]. - The number of First-in-Class (FIC) drugs developed in China has risen from 9 in 2015 to 120 in 2024, indicating a substantial increase in innovation [25][26]. Section 2: Continued BD Opportunities - PD-(L)1 plus is identified as a cornerstone for next-generation cancer treatments, with significant demand and potential for new products [51]. - The report notes that ADCs are transitioning towards more differentiated targets, focusing on unmet clinical needs, with promising candidates like PD-L1, DLL3, and EGFR [51]. - The GLP-1 market is experiencing rapid growth, with a focus on multi-target, oral, combination, and long-acting formulations [51]. Section 3: Investment Recommendations - For PD-(L)1 plus, companies such as Kangfang Biotech, Shansheng Pharmaceutical, and Junshi Biosciences are recommended for investment due to their strong pipelines [5]. - In the ADC space, companies like Fuhong Hanlin and Zai Lab are highlighted for their potential in addressing unmet clinical needs [5]. - In the GLP-1 sector, firms such as Borui Pharmaceutical and Zai Lab are noted for their promising developments [5].